In accordance with privacy legislation, Kedrion S.p.A., controller of the data collected through this website, hereby informs the user that this website does not use profiling cookies to send advertising messages in line with the preferences expressed when browsing the web. This website installs third party cookies. By continuing to browse, including by scrolling down and clicking on website elements, the user agrees to the company’s cookies policy.
For more information, also as regards the technical cookies used by the website and to object to the use of individual cookies, reference should be made to the complete cookies disclosure.
You are now leaving Kedrion Corporate site. Medical information including licensed uses may be different outside of the EU countries.
NO
YES
-
CORPORATE - 31-10-2017
Kedrion and Cerus enter distribution agreement for INTERCEPT in Italy
Agreement covers complete INTERCEPT product line: platelets, plasma and red blood cells
read more -
CORPORATE - 25-08-2017
Kedrion Biopharma and Kamada Ltd Receive FDA Approval for KEDRAB®
The product is approved for post-exposure prophylaxis against rabies infection
read more -
CORPORATE - 19-04-2017
Kedrion Biopharma signs agreement with European Hemophilia Consortium (EHC)
The agreement aims to improve patient access to coagulation disorders treatments in Europe
read more -
CORPORATE - 24-03-2017
New company AO Kirov Plasma established in Russia
It’s a joint venture between Kedrion Biopharma, Nacimbio and Pharmastandard
read more
For more information please contact: pressoffice@kedrion.com
Where 